metastatic cancer

The conversation starts with a small detail that quickly becomes memorable. There is no coffee. On a podcast built around conversations over coffee, Professor Ricky Dylan Frazer, Consultant Medical Oncologist at Velindre Cancer Centre, Deputy CEO of the Immuno-Oncology Clinical…

In oncology, progress is measured in survival rates, response curves, and treatment gains. But those numbers rest on a quieter assumption: that health systems can deliver what science makes possible. When they cannot, progress becomes uneven—not in discovery, but in…

In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…

Chimeric antigen receptor natural killer T (CAR-NKT) cell therapy, a novel form of immunotherapy, is emerging as a promising ‘off-the-shelf’ treatment for patients with pancreatic cancer. In a study published in PNAS, November 21, 2025, U.S. investigators report that CAR-NKT cells…

Aerobic exercise can reduce the risk of developing metastatic cancer by 73%. Using both human epidemiological data and in vivo mouse models of melanoma metastasis, Israeli investigators report in Cancer Research (November 15) that high-intensity aerobic exercise increases glucose consumption…

Patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma should be offered next-generation sequencing (NGS) for profiling tumour samples, concludes an expert panel from the European Society for Medical Oncology (ESMO) in their review (Mosele…